除了多发性硬化,CD40L/CD40通路还会影响与自身免疫有关的一系列疾病,靶向该通路的产品有潜力治疗多种疾病。
公开资料显示,除了frexalimab,全球范围内还有几款靶向CD40L的新药已经进入临床研究阶段,比如dazodalibep已经在针对干燥综合征的临床研究中获得疗效验证,目前正在开展3期临床研究;dapirolizumab pegol单抗正在中国开展治疗系统性红斑狼疮的3期临床研究;IBI355正在中国开展1期临床研究,目前拟开发适应症为系统性红斑狼疮、原发性干燥综合征;TNX-1500已经获美国FDA批准开展临床研究,目标适应症为预防造血干细胞移植后的移植物抗宿主病(GvHD)以及其他自免疾病,等等。限于篇幅,此处不再一一赘述。希望这些在研新药早日在临床中取得进一步突破,尽快造福患者。参考资料:[1]中国药物临床试验登记与信息公示平台官网.Retrieved May 13,2024, From https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d
[2]Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS. Retrieved February 15, 2024 from https://www.sanofi.com/en/media-room/press-releases/2024/2024-02-15-13-00-00-2829933
[3] Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis. Retrieved April 17, 2024 from https://www.sanofi.com/en/media-room/press-releases/2024/2024-04-17-05-00-00-2864225
[4] Sanofi R&D day. Retrieved December 7, 2023, from https://www.sanofi.com/assets/dotcom/content-app/events/investor-presentation/2023/r-and-d-day-2023/Presentation.pdf